Searching therapeutic strategy of new coronavirus pneumonia from angiotensin-converting enzyme 2: the target of COVID-19 and SARS-CoV.
Eur J Clin Microbiol Infect Dis
; 39(6): 1021-1026, 2020 Jun.
Artículo
en Inglés
| MEDLINE | ID: covidwho-1718753
ABSTRACT
Since December 2019, the infection of the new coronavirus (COVID-19) caused an outbreak of new coronavirus pneumonia in Wuhan, China, and caused great public concern. Both COVID-19 and SARS-CoV belong to the coronavirus family and both invade target cells through ACE2. An in-depth understanding of ACE2 and a series of physiological and physiological changes caused by the virus invading the human body may help to discover and explain the corresponding clinical phenomena and then deal with them timely. In addition, ACE2 is a potential therapeutic target. This article will summarize the role of ACE2 in multiple organ damage caused by COVID-19 and SARS-CoV, targeted blocking drugs against ACE2, and drugs that inhibit inflammation in order to provide the basis for subsequent related research, diagnosis and treatment, and drug development.
Palabras clave
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Neumonía
/
Neumonía Viral
/
Inhibidores de la Enzima Convertidora de Angiotensina
/
Infecciones por Coronavirus
/
Peptidil-Dipeptidasa A
/
Síndrome Respiratorio Agudo Grave
/
Coronavirus Relacionado al Síndrome Respiratorio Agudo Severo
/
Pandemias
/
Betacoronavirus
Tipo de estudio:
Estudio pronóstico
Tópicos:
Covid persistente
Límite:
Humanos
Idioma:
Inglés
Revista:
Eur J Clin Microbiol Infect Dis
Asunto de la revista:
Enfermedades Transmisibles
/
Microbiologia
Año:
2020
Tipo del documento:
Artículo
País de afiliación:
S10096-020-03883-y
Similares
MEDLINE
...
LILACS
LIS